Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease –Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of disease in PD– –IND-enabling...

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases,...